Angiogenesis inhibitor therapies for metastatic renal cell carcinoma: Effectiveness, safety and treatment patterns in clinical practice-based on medical chart review

BJU International

Volumn 105, Issue 9, 2010, Pages 1247-1254

  Choueiri, Toni K ^a   Duh, Mei Sheng ^b   Clement, Jessica ^c   Brick, Ashley J ^a   Rogers, Miranda J ^a   Kwabi, Christabel ^c   Shah, Karishma ^c   Percy, Andrew G ^c   Antràs, Lucia ^b   Jayawant, Sujata S ^b   Chen, Kristina ^b   Wang, Si Tien ^b   Luka, Andi ^b   Neary, Maureen P ^d   McDermott, David ^c   Oh, William K ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b ANALYSIS GROUP   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^d GLAXOSMITHKLINE   (United States)

Author keywords

Angiogenesis inhibitor; Effectiveness; Renal cell carcinoma; Safety

Indexed keywords

BEVACIZUMAB; SORAFENIB; SUNITINIB;

ADULT; AGED; AGEUSIA; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BONE METASTASIS; BRAIN METASTASIS; CHEMOTHERAPY INDUCED EMESIS; CLINICAL PRACTICE; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEMALE; HAND FOOT SYNDROME; HEMATURIA; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MUCOSA INFLAMMATION; NAUSEA; OFF LABEL DRUG USE; OVERALL SURVIVAL; PAIN; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; RASH; SIDE EFFECT; WOUND HEALING IMPAIRMENT;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; CARCINOMA, RENAL CELL; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MEDICAL RECORDS; MIDDLE AGED; NEOPLASM METASTASIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 77950814307     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2009.08972.x     Document Type: Article

References (20)

1. Motzer RJ, Bander NH, Nanus DM. Renal cell carcinoma. N Engl J Med 1996 335 : 865 875
2. Motzer RJ, Russo P. Systemic therapy for renal cell carcinoma. J Urol 2000 163 : 408 417 (Pubitemid 30060482)
3. Wirth MP. Immunotherapy for metastatic renal cell carcinoma. Urol Clin North Am 1993 20 : 283 295 (Pubitemid 23154478)
4. Law TM, Motzer RJ, Mazumdar M et al. Phase II randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma. Cancer 1995 76 : 824 832
5. Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007 356 : 115 124 (Pubitemid 46089672)
6. Motzer RJ, Hutson TE, Tomczak P et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal-cell carcinoma. J Clin Oncol 2009 27 : 3584 3590
7. Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell-renal-cell carcinoma. N Engl J Med 2007 356 : 125 134
8. Bukowski RM, Kabbinavar FF, Figlin RA et al. Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. J Clin Oncol 2007 25 : 4536 4541
9. Yang JC, Haworth L, Sherry RM et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003 349 : 427 434 (Pubitemid 36910021)
10. Escudier B, Pluzanska A, Koralewski P et al. Bevacizumab plus interferon alfa-2a for the treatment of metastatic renal cell carcinoma: a randomized, double-blind phase III trial. Lancet 2007 370 : 2103 2111 (Pubitemid 350296300)
11. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000 92 : 205 216 (Pubitemid 30099779)
12. Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0. Available at: http://ctep.cancer.gov/forms/CTCAEv3.pdf. Accessed June 2008
13. Parmar MKB, Machin D. Survival Analysis: a Practical Approach.
14. Szczylik C, Demkov T, Staehler M et al. Randomized phase II trial of first-line treatment with sorafenib versus interferon in patients with advanced renal cell carcinoma. Final results Abstract and associated presentation 2007 ASCO Annual Meeting. Available at: http://www.asco.org/ASCO/ Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=Abstract-detail- view&confide=47&abstracted=34559. Accessed August 2008
15. Motzer RJ, Figlin RA, Hutson TE et al. Sunitinib versus interferon-alfa (IFN-α) as first-line treatment of metastatic renal cell carcinoma (mRCC): Updated results and analysis of prognostic factors. Abstract and associated presentation. 2007 ASCO Annual Meeting. Available at: http://www.asco.org/ASCO/ Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=Abstract-detail- view&confide=47&abstracted=32015. Accessed September 2008
16. Henderson CA, Bukowski RM, Stadler WM et al. The advanced renal cell carcinoma sorafenib (ARCCS) expanded access trial: subset analysis of patients with brain metastasis. 2007 ASCO Annual Meeting. Available at: http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview= Abstract-detail-view&confide=47&abstracted=33876. Accessed September 2008
17. Riechelmann RP, Chin S, Wang L et al. Sorafenib for metastatic renal cancer: the princess Margaret experience. Am J Clin Oncol 2008 31 : 182 187 (Pubitemid 351519171)
18. Zimmermann K, Schmittel A, Steiner U et al. Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenib. Oncology 2009 76 : 350 354
19. van der Veldt AA, Boven E, Helgason HH et al. Predictive factors for sever toxicity of sunitinib in unselected patients with advanced renal cell cancer. Br J Cancer 2008 99 : 259 265
20. Duh MS, Fournier A-A, Moyneur E. et al. Dosing and switching patterns for renal cell carcinoma (RCC) patients receiving selected angiogenesis inhibitor therapies. Poster presentation at 44th Annual Meeting of the American Society of Clinical Oncology (ASCO); 2008; Chicago, IL